Begin patient enrollment for SOD1-ALS clinical trial
Delivered after the deadline (15 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 May 2024
- Due
- 30 Sep 2024
- Delivered
- 15 Oct 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patient enrollment in a Phase I/II clinical trial is expected to begin in the third quarter of 2024.”
What we found
Evidence strength A What the grades mean
The company announced the first patient was dosed in the SOD1-ALS clinical trial on October 15, 2024, which occurred after the third quarter 2024 deadline.
-
A uniQure N.V. 8-K filed 2024-10-15
“October 15, 2024 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the Phase I/II clinical trial of AMT-162” ✓ confirmed on the page
Market reaction: the shares moved +11.7% against the S&P 500 over the three sessions around the disclosure (14 Oct 2024 to 17 Oct 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- SOD1-ALS clinical trial enrollment
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-QURE-001868 · Corrections policy